The estimated Net Worth of Nazila Habibizad is at least $3.03 millió dollars as of 1 October 2022. Ms Habibizad owns over 1,557 units of Global Blood Therapeutics stock worth over $2,717,683 and over the last 3 years she sold GBT stock worth over $314,315.
Ms has made over 7 trades of the Global Blood Therapeutics stock since 2022, according to the Form 4 filled with the SEC. Most recently she exercised 1,557 units of GBT stock worth $106,639 on 1 October 2022.
The largest trade she's ever made was exercising 29,755 units of Global Blood Therapeutics stock on 27 September 2022 worth over $570,403. On average, Ms trades about 5,577 units every 27 days since 2022. As of 1 October 2022 she still owns at least 39,680 units of Global Blood Therapeutics stock.
You can see the complete history of Ms Habibizad stock trades at the bottom of the page.
Nazila Habibizad is the Exec. VP of Operations at Global Blood Therapeutics.
Ms Habibizad is 58, she's been the Exec. VP of Operations of Global Blood Therapeutics since . There are 14 older and 6 younger executives at Global Blood Therapeutics. The oldest executive at Global Blood Therapeutics Inc. is Willie Brown, 86, who is the Independent Director.
Nazila's mailing address filed with the SEC is C/O GLOBAL BLOOD THERAPEUTICS, INC., 181 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080.
Over the last 9 years, insiders at Global Blood Therapeutics have traded over $164,753,446 worth of Global Blood Therapeutics stock and bought 255,000 units worth $8,595,265 . The most active insiders traders include Advisors Llcperceptive Life..., Rock Ventures Ii, L.P.Third... és Kevin P Starr. On average, Global Blood Therapeutics executives and independent directors trade stock every 14 days with the average trade being worth of $3,133,144. The most recent stock trade was executed by Nazila Habibizad on 1 October 2022, trading 1,557 units of GBT stock currently worth $106,639.
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.
Global Blood Therapeutics executives and other stock owners filed with the SEC include: